Metastatic Castration Sensitive Prostate Cancer (mCSPC) (DBCOND0154644)

Identifiers

Synonyms

Metastatic Castration Sensitive Prostate Cancer / Metastatic Castration-sensitive Prostate Cancer / Metastatic Castrate Sensitive Prostate Cancer / Metastatic Castrate-sensitive Prostate Cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Abiraterone	An antiandrogen used in the treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.	Steroid 17-alpha-hydroxylase/17,20 lyasetarget Albumincarrier Alpha-1-acid glycoprotein 1carrier Cytochrome P450 3A4enzyme Sulfotransferase 2A1enzyme Multidrug resistance-associated protein 1transporter Cytochrome P450 2D6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A5enzyme Solute carrier organic anion transporter family member 1B1transporter
Apalutamide	An androgen receptor inhibitor used to treat non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.	Androgen receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier family 22 member 2transporter Organic anion transporter 3transporter Multidrug and toxin extrusion protein 2transporter GABA(A) Receptortarget Multidrug and toxin extrusion protein 1transporter Albumincarrier
Enzalutamide	A second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.	Albumincarrier Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Androgen receptortarget Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2B6enzyme Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05701007	Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland	Abiraterone Apalutamide Cabazitaxel Degarelix Docetaxel Enzalutamide Goserelin Leuprolide Lutetium Lu-177 Radium Ra-223 Triptorelin	Not Available	Not Available	completed
NCT02020070	Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy	No drug interventions	treatment	2	active_not_recruiting
NCT04601441	Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan	Apalutamide	screening	4	recruiting
NCT05149131	A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer	No drug interventions	Not Available	Not Available	completed
NCT06120491	Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents	Abiraterone Darolutamide Enzalutamide Saruparib	treatment	3	recruiting
NCT04887506	TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer	No drug interventions	treatment	3	completed
NCT04666129	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT04497844	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	No drug interventions	treatment	3	active_not_recruiting
NCT05884398	A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC	Apalutamide	treatment	3	recruiting